Home LiteratureArticle Details
PMID: 11739496 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

Engagement of OX40 enhances antigen-specific CD4(+) T cell mobilization/memory development and humoral immunity: comparison of alphaOX-40 with alphaCTLA-4.

Journal of immunology (Baltimore, Md. : 1950) ·Vol. 167 ·No. 12 ·2001-12-15 ·Pages 6804-11

Evans DE, Prell RA, Thalhofer CJ, Hurwitz AA, Weinberg AD

Abstract

Increasing the long-term survival of memory T cells after immunization is key to a successful vaccine. In the past, the generation of large numbers of memory T cells in vivo has been difficult because Ag-stimulated T cells are susceptible to activation-induced cell death. Previously, we reported that OX40 engagement resulted in a 60-fold increase in the number of Ag-specific CD4(+) memory T cells that persisted 60 days postimmunization. In this report, we used the D011.10 adoptive transfer model to examine the kinetics of Ag-specific T cell entry into the peripheral blood, the optimal route of administration of Ag and alphaOX40, and the Ag-specific Ab response after immunization with soluble OVA and alphaOX40. Finally, we compared the adjuvant properties of alphaOX40 to those of alphaCTLA-4. Engagement of OX-40 in vivo was most effective when the Ag was administered s.c. Time course studies revealed that it was crucial for alphaOX40 to be delivered within 24-48 h after Ag exposure. Examination of anti-OVA Ab titers revealed a 10-fold increase in mice that received alphaOX40 compared with mice that received OVA alone. Both alphaOX40 and alphaCTLA-4 increased the percentage of OVA-specific CD4(+) T cells early after immunization (day 4), but alphaOX40-treated mice had much higher percentages of OVA-specific memory CD4(+) T cells from days 11 to 29. These studies demonstrate that OX40 engagement early after immunization with soluble Ag enhances long-term T cell and humoral immunity in a manner distinct from that provided by blocking CTLA-4.

MeSH Terms
Abatacept Adjuvants, Immunologic/administration & dosage Adoptive Transfer Animals Antibodies/administration & dosage Antigens/administration & dosage,immunology Antigens, CD Antigens, Differentiation/immunology,metabolism Blood/immunology CD4-Positive T-Lymphocytes/immunology,transplantation CTLA-4 Antigen Cell Movement Cell Survival Cytokines/biosynthesis Female Immunoconjugates Immunoglobulin G/biosynthesis Immunologic Memory Kinetics Lymphocyte Activation Mice Mice, Inbred BALB C Ovalbumin/administration & dosage,immunology Receptors, OX40 Receptors, Tumor Necrosis Factor Tumor Necrosis Factor Receptor Superfamily, Member 7/immunology,metabolism
Chemicals
Adjuvants, Immunologic Antibodies Antigens Antigens, CD Antigens, Differentiation CTLA-4 Antigen Ctla4 protein, mouse Cytokines Immunoconjugates Immunoglobulin G Receptors, OX40 Receptors, Tumor Necrosis Factor Tnfrsf4 protein, mouse Tumor Necrosis Factor Receptor Superfamily, Member 7 Abatacept Ovalbumin
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Evans D E
Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, Portland, OR 97213, USA.
Prell R A
Thalhofer C J
Hurwitz A A
Weinberg A D
Article Info
Journal
Journal of immunology (Baltimore, Md. : 1950)
Abbr.
J Immunol
ISSN
0022-1767
Published
2001-12-15
Pages
6804-11
Language
English
Region
United States
NLM ID
2985117R
Subset
IM
Grants
NCI NIH HHS · R01 CA81638-03 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com